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Background: Homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol
(MHPG) are the major monoamine metabolites in the central nervous system (CNS). Their cerebrospinal fluid (CSF)
concentrations, reflecting the monoamine turnover rates in CNS, are partially under genetic influence and have
been associated with schizophrenia. We have hypothesized that CSF monoamine metabolite concentrations
represent intermediate steps between single nucleotide polymorphisms (SNPs) in genes implicated in
monoaminergic pathways and psychosis.
Methods: We have searched for association between 119 SNPs in genes implicated in monoaminergic pathways
[tryptophan hydroxylase 1 (TPH1), TPH2, tyrosine hydroxylase (TH), DOPA decarboxylase (DDC), dopamine
beta-hydroxylase (DBH), catechol-O-methyltransferase (COMT), monoamine oxidase A (MAOA) and MAOB] and
monoamine metabolite concentrations in CSF in 74 patients with psychotic disorder.
Results: There were 42 nominally significant associations between SNPs and CSF monoamine metabolite
concentrations, which exceeded the expected number (20) of nominal associations given the total number of tests
performed. The strongest association (p = 0.0004) was found between MAOB rs5905512, a SNP previously reported
to be associated with schizophrenia in men, and MHPG concentrations in men with psychotic disorder. Further
analyses in 111 healthy individuals revealed that 41 of the 42 nominal associations were restricted to patients with
psychosis and were absent in healthy controls.
Conclusions: The present study suggests that altered monoamine turnover rates in CNS reflect intermediate steps
in the associations between SNPs and psychosis.
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Schizophrenia is a disorder affecting approximately 1% of
the world’s population and with heritability up to 80%
[1]. Many gene variations have been associated with
the disorder, however the results have been ambiguous
and difficult to replicate until recently, when genome wide
analyses of several thousands of individuals have identified
an increasing number of loci associated with schizophre-
nia [2]. Measurable biological markers may form inter-
mediate steps between gene variations and the phenotype,
i.e. the psychotic disorder, and associations between
the biological measures and gene variants may be more
robust than the associations between gene variants and
the disorder itself.
Homovanillic acid (HVA), 5-hydroxyindoleacetic acid
(5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG)
are the major degradation products of the monoamines
dopamine, serotonin and noradrenaline, respectively.
Cerebrospinal fluid (CSF) HVA, 5-HIAA and MHPG con-
centrations are considered to reflect the turnover rates of
the monoamines in the central nervous system (CNS).
Concentrations of HVA and 5-HIAA in ventricular, cister-
nal, and lumbar CSF show a craniocaudal gradient [3,4].
Postmortem human studies have shown that CSF HVA
and 5-HIAA reflect brain HVA and 5-HIAA concentra-
tions [5,6]. Correlations have been found between MHPG
concentrations in CSF and MHPG concentrations in
hypothalamus, temporal cortex, and pons in human aut-
opsy cases [6]. Studies in human twins and other primates
have shown that monoamine metabolite concentrations
are partially under genetic influence [7,8].
Schizophrenia has been associated with monoamine
metabolite concentrations, mainly HVA. HVA concentra-
tions have been reported to be significantly lower in drug-
free schizophrenic patients compared to controls [9,10].
Both quetiapine and olanzapine administration have been
associated with a significant increase in CSF HVA [11,12].
Tryptophan hydroxylase (TPH) catalyses the conversion
of tryptophan to 5-hydroxytryptophan (Figure 1), which is
the rate-limiting reaction in the biosynthesis of serotonin
[13]. Two isoforms, TPH1 and TPH2, have been identi-
fied, encoded by two different genes, i.e. TPH1 and TPH2,
located on chromosome 11p15.3–p14 and 12q21.1,
respectively. Both TPH1 and TPH2 are expressed in the
human brain and TPH1 may be preferentially expressed
in the developing brain [14].
Tyrosine hydroxylase (TH) catalyzes the hydroxylation
of L-tyrosine to 3,4-dihydroxy-L-phenylananine (Figure 1),
which is the rate-limiting step in the biosynthesis of
catecholamines [15]. The TH gene is located on chromo-
some 11p15.5.
DOPA decarboxylase (DDC), also known as aromatic
L-amino acid decarboxylase, catalyzes the decarboxylation
of both L-DOPA to dopamine and 5-hydroxytryptophanto serotonin [16]. Thus, this enzyme is involved in the
dopamine and serotonin pathways and indirectly in the
noradrenaline pathway (Figure 1). The DDC gene is
located on chromosome 7p12.1 and consists of 15 exons
spanning more than 75 kb [16].
Dopamine beta-hydroxylase (DBH), localised in vesi-
cles of noradrenergic and adrenergic cells [17], catalyses
the conversion of dopamine to noradrenaline (Figure 1).
DBH knockout mice lack noradrenaline and moreover
show attenuated dopamine concentrations in various
brain areas, due to interactions between noradrenergic
and dopamine systems [18]. The DBH gene is located on
chromosome 9q34.
Catechol-O-methyltransferase (COMT) catalyses the
methyl conjugation and thus inactivation of the cate-
cholamines and is the most important regulator of the
prefrontal dopamine function [19]. This enzyme is not
involved in the degradation of serotonin (Figure 1). The
COMT gene is located on chromosome 22q11.2.
Monoamine oxidases are important enzymes for the
degradation of various biogenic amines, including catechol-
amines and serotonin (Figure 1). There are two forms of the
enzyme, monoamine oxidase A (MAOA) and monoamine
oxidase B (MAOB), located throughout the brain in the
outer membrane of mitochondria and encoded by two
separate genes [20]. In humans, MAOA preferentially oxi-
dizes serotonin and noradrenaline, whereas MAOB oxidizes
dopamine [20]. The MAOA and MAOB genes are closely
linked on the chromosome Xp11.23 and both include 15
exons with identical intron-exon organization, implying that
they are derived from the same ancestral gene [21].
In the present study, we considered dopamine, serotonin,
and noradrenaline turnover rates in CNS as probable inter-
mediate steps between gene variants and schizophrenia.
We hypothesized that single nucleotide polymorphisms
(SNPs) in genes encoding the enzymes TPH1, TPH2, TH,
DDC, DBH, COMT, MAOA and MAOB, all implicated in
the basic biochemical pathways of the monoamines, affect
the concentrations of HVA, 5-HIAA, and MHPG in the
CSF of psychotic patients.
Methods
Subjects
Psychotic patients were initially recruited among inpa-
tients at four psychiatric university clinics in Stockholm
County between the years 1973 and 1987. After admit-
tance patients were asked to participate in pharmaco-
logical and/or biological research projects as previously
described [22]. Patients were usually observed for at
least 48 hours without any antipsychotic medication
before CSF was drawn by a lumbar puncture.
Three to 34 years after the first investigation, when
CSF was obtained, subjects were asked to participate
in genetic research and whole blood was drawn for
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Figure 1 Basic biochemical pathways of serotonin, dopamine and noradrenaline.
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structured interview [23] and to sign a request permitting
the researchers to take part of his/her medical records.
Available records were scrutinized by a researcher to
obtain a life-time diagnosis according to DSM-III-R and
DSM-IV. In 2010, 22 to 36 years after the initial CSF sam-
pling, hospital discharge diagnoses were obtained from
the Swedish psychiatric inpatient register (SPIR), which is
a register based on the patient’s identification number,
covering all inpatient hospitalizations in Sweden since
1973. For each hospitalization the diagnosis was recorded
according to the International Classification of Diseases,
8th, 9th or 10th revisions. The majority of the participating
individuals had experienced several hospitalizations, but
each patient was given only one diagnosis, following a
diagnostic hierarchy as previously described [24,25]. It was
not possible to retrieve all medical records and several of
the patients were not willing to participate in a diagnostic
interview. Therefore, the final diagnoses were based on
those obtained from SPIR.
Further analyses, investigating healthy individuals, were
conducted for SNPs that were found to be associated with
HVA, 5-HIAA or MHPG concentrations in psychotic pa-
tients, in order to evaluate whether the effects of the asso-
ciated SNPs on the specific monoamine metabolites were
restricted to patients with psychosis. Unrelated healthy
Caucasians were investigated with lumbar puncture be-
tween the years 1973 and 1987 to participate in biological
research. Eight to 20 years after the first investigation,when CSF was sampled, the subjects were interviewed to
re-assess the absence of psychiatric morbidity as previ-
ously described [26]. At this interview whole blood was
drawn for genotyping.
The study was conducted in accordance with the Decla-
ration of Helsinki and approved by the Ethics Committee
of the Karolinska University Hospital. Written informed
consent was obtained from all the participating subjects.
CSF monoamine metabolite concentrations
CSF samples (12.5 ml) were drawn by lumbar puncture
with the patients and controls in a sitting or recumbent
position between 8 and 9 a.m, after at least 8 h of bed-rest
and absence of food intake or smoking. 5-HIAA, HVA,
and MHPG concentrations were measured by mass frag-
mentography with deuterium-labeled internal standards
[27]. Back-length was defined as the distance between
the external occipital protuberance and the point of
needle insertion.
DNA analysis
Genomic DNA was extracted from whole blood [28].
SNPs in TPH1 (n = 10), TPH2 (n = 21), TH (n = 10),
DDC (n = 24), DBH (n = 25), COMT (n = 16), MAOA
(n = 6) and MAOB (n = 7) were included. These SNPs
were either candidate SNPs (n = 28) reported to be associ-
ated with schizophrenia, other mental disorders, enzyme
function or monoamine metabolite concentrations, or
tag-SNPs (n = 91), selected using HapMap to cover the
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ing was performed using the Illumina BeadStation 500GX
and the 768-plex Illumina Golden Gate assay (Illumina
Inc., San Diego, CA, USA) [29].
Statistical analysis
Hardy-Weinberg equilibrium (HWE) was tested using
exact significance as implemented in STATA 12.1. Minor
allele frequencies were measured using STATA 12.1.
Normality of residuals was checked graphically with
STATA 12.1. The associations between SNPs and CSF
monoamine metabolite concentrations were tested with
multiple linear regression (STATA 12.1), where concen-
tration was modeled as a linear function of the allele
count (of each SNP separately) and three to five covari-
ates. In the case of psychotic patients, back-length, gen-
der, age at lumbar puncture, diagnosis (i.e. schizophrenia
spectrum psychosis or other psychosis) and use of anti-
psychotics were included as covariates. Antipsychotic
treatment was considered as present if the patient had
taken antipsychotics during a three-week period prior to
the lumbar puncture. In the case of healthy controls,
back-length, gender and age at lumbar puncture were in-
cluded as covariates. MAOA and MAOB are located
on chromosome X, and therefore the analyses of these
genes were conducted separately for men and women.
In psychotic patients, we conducted 396 tests in total,
as we have included 119 SNPs tested separately for the
three different monoamine metabolites and moreover
the X-linked MAOA and MAOB SNPs were tested sep-
arately in men and women. Adjustments for multiple
testing were performed using Bonferroni correction
taking into account a/the total number of tests con-
ducted (α = 0.05/396 = 1.26x10−4) and b/ the total num-
ber of tests conducted, restricted to the 28 candidate
SNPs (α = 0.05/90 = 5.56x10−4).
Results
Totally 74 patients (45 men and 29 women) were
included in the present study. Their mean age ± standard
deviation was 30.4 ± 7.2 years at lumbar puncture,
whereas the mean age of disease onset was 27.6 ± 7.8.
A minority (n = 26) of the patients were treated with anti-
psychotics at the time of lumbar puncture, whereas the
majority (n = 36) were free from antipsychotic medication
since three weeks or longer. Sixty-four patients were diag-
nosed with schizophrenia spectrum disorder (schizophrenia
n = 60, schizoaffective disorder n = 4) and ten with other
psychosis (psychosis not otherwise specified (NOS) n = 7,
delusional disorder n = 1, bipolar disorder n = 1, alcohol
induced psychotic disorder n = 1).
We conducted separate analyses, in order to evaluate
how the SPIR-derived diagnoses conformed to other
diagnostic tools used in the present study. Evaluationswere made based on information originating from the
medical records in 52 of the patients resulted in a diag-
nosis of a psychotic disorder in 98% of these individuals.
Of 44 patients participating in a diagnostic interview
[23], 91% displayed a psychotic disorder according to
the SCID-I algorithm. Previous studies have also shown
that the Swedish in-patient resister-based diagnoses of
schizophrenia spectrum psychosis have a high validity,
as 85% to 94% of these patients displayed these diagno-
ses when research psychiatrists made a diagnostic evalu-
ation using information from medical records and a
structured clinical interview [24].
In the 74 psychotic patients, 119 SNPs in eight genes en-
coding enzymes implicated in the monoamine metabolism
were selected and genotyped. The minor allele frequency
for the selected markers ranged from 2% to 49%. Departure
from HWE (p-value < 0.05) was found in four of the 119
SNPs analyzed, i.e. DDC rs4947510, DDC rs921451, TPH2
rs1352250 and COMT rs165774. The residuals of the nom-
inal associations were approximately normally distributed.
In psychotic patients, the mean (S.D.) concentrations of
the three monoamine metabolites were: HVA 178.6
(79.3) nmol/L; 5-HIAA 93.1 (34) nmol/L; MHPG 43.3
(9.3) nmol/L. Twelve, 12 and 18 of the investigated poly-
morphisms (Tables 1, 2 and 3) were found to be nominally
associated with CSF HVA, 5-HIAA and MHPG concen-
trations, respectively.
It may be argued that the genes selected for the present
report are highly likely to influence monoamine metabol-
ite concentrations in CSF, and giving strong a priori
hypotheses, it has been suggested that correction for mul-
tiple testing is not necessary [30]. Therefore, we report all
the nominal associations. Taking into account the total
number of tests conducted, we also applied a Bonferroni
correction for multiple testing (α = 0.05/396 = 1.26 × 10−4)
and none of the nominal associations were found to be
statistically significant. As a less conservative alternative,
we applied a Bonferroni correction taking into account
the total number of tests conducted, restricted to the 28
candidate SNPs (α = 0.05/90 = 5.56x10−4). Using this cor-
rection, there was one significant result, i.e. the association
between MAOB rs5905512 and CSF MHPG concentra-
tions in psychotic men. In total, there were 42 nominal as-
sociations, which exceeded the expected number (20) of
nominal associations given the 396 calculations performed
[(119 SNPs + additional 13 calculations because of the
gender-based calculations on the X-chromosome) × 3
monoamine metabolites)].
The associations (n = 42) between SNPs and monoamine
metabolite concentrations which gave evidence for
nominal significance in psychosis were tested in healthy
individuals. There were 111 Caucasians (63 men and
48 women) included for that purpose. Their mean ages ±
standard deviation were 28.4 ± 7.5 years at lumbar
Table 1 SNPs nominally associated with CSF HVA concentrations in psychotic patients
Patients with psychosis (n = 74; 45 men, 29 women) Healthy controls (n = 111; 63 men, 48 women)
HVA mean (S.D.) 178.6 (79.3) nmol/l 167.5 (68.4) nmol/l
Gene SNP MAF(%) HWE P MAF(%) HWE P
DDC rs11238133 36 0.211 0.004 41 1.000 0.757
DDC rs6951648 19 0.273 0.005 17 0.735 0.297
DDC rs10499696 11 0.186 0.009 9 0.594 0.681
DDC rs921451 42 0.018 0.011 43 0.564 0.661
DDC rs9942686 21 0.723 0.017 23 1.000 0.305
TH rs10770141 33 0.608 0.023 40 1.000 0.433
TPH1 rs211105 31 0.785 0.029 25 0.449 0.292
TH rs10840491 16 0.680 0.035 12 0.640 0.433
DDC rs6593011 15 0.652 0.038 13 0.208 0.959
COMT rs165774 32 0.003 0.043 30 0.258 0.650
TPH2 rs1872824 34 0.606 0.047 33 0.830 0.685
TH rs10840489 18 1.000 0.048 14 1.000 0.357
Minor allele frequencies (MAF), p-values of testing for Hardy–Weinberg equilibrium (HWE) and p-values (P) from multiple linear regressions of single nucleotide
polymorphisms (SNPs) nominally associated with homovanillic acid (HVA) concentrations in the cerebrospinal fluid of psychotic patients and the corresponding
association statistics among healthy controls.
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centrations of the three monoamine metabolites were:
HVA 167.5 (68.4) nmol/L; 5-HIAA 90.8 (36.2) nmol/L;
MHPG 41.7 (8.1) nmol/L. The minor allele frequency for
the selected markers ranged from 4% to 50%. Departure
from Hardy-Weinberg equilibrium (p < 0.05) was found in
two of the SNPs analyzed (Table 3). The residuals were
approximately normally distributed. With the exception ofTable 2 SNPs nominally associated with CSF 5-HIAA concentr
Patients with psychosis (n = 74; 45 men
5-HIAA mean (S.D.) 93.1 (34) nmol/l
Gene SNP MAF (%) HWE
MAOB(women) rs2311013 3 1.000
MAOB(women) rs1181252 3 1.000
DDC rs9942686 21 0.723
DDC rs11238133 36 0.211
DBH rs1611118 7 1.000
DDC rs11238131 30 0.784
MAOA (men) rs5906957 31
DDC rs11575535 4 1.000
TPH1 rs1799913 42 0.096
DBH rs6271 3 1.000
MAOA (men) rs4301558 36
MAOA (men) rs3027396 36
Minor allele frequencies (MAF), p-values of testing for Hardy–Weinberg equilibrium
polymorphisms (SNPs) nominally associated with 5-hydroxyindoleacetic acid (5-HIA
corresponding association statistics among healthy controls. MAOA and MAOB are l
separately for men and women.a nominal association between TPH1 rs211105 and MHPG
concentrations, no associations were found (Table 3).
In the present study, mean CSF HVA and 5-HIAA
concentrations were not found to be associated with
antipsychotic treatment, whereas mean CSF MHPG con-
centration was significantly lower in patients who were
prescribed antipsychotics compared to antipsychotic-free
patients. We have included the use of antipsychotics as aations in psychotic patients
, 29 women) Healthy controls (n = 111; 63 men, 48 women)
90.8 (36.2) nmol/l
P MAF (%) HWE P
0.009 4 1.000 0.866
0.009 4 1.000 0.053
0.009 23 1.000 0.069
0.012 41 1.000 0.516
0.014 7 0.397 0.895
0.019 32 0.826 0.829
0.027 17 0.089
0.035 4 1.000 0.302
0.039 41 0.334 0.330
0.047 5 1.000 0.528
0.048 20 0.123
0.048 21 0.299
(HWE) and p-values (P) from multiple linear regressions of single nucleotide
A) concentrations in the cerebrospinal fluid of psychotic patients and the
ocated on chromosome X and the analyses were therefore conducted
Table 3 SNPs nominally associated with CSF MHPG concentrations in psychotic patients
Patients with psychosis (n = 74; 45 men, 29 women) Healthy controls (n = 111; 63 men, 48 women)
MHPG mean (S.D.) 43.3 (9.3) nmol/l 41.7 (8.1) nmol/l
Gene SNP MAF(%) HWE P MAF (%) HWE P
MAOB (men) rs5905512 47 0.0004 50 0.479
MAOB (men) rs1799836 38 0.0008 44 0.483
DDC rs11575535 4 1.000 0.005 4 1.000 0.126
TPH1 rs4537731 44 0.475 0.007 40 0.047 0.646
DDC rs6592961 28 0.400 0.008 29 0.104 0.855
TPH1 rs7933505 41 0.148 0.010 41 0.334 0.342
DDC rs7809758 40 0.811 0.013 38 0.159 0.956
TPH1 rs7122118 43 0.239 0.014 40 0.029 0.821
DBH rs6271 3 1.000 0.017 5 1.000 0.340
TPH1 rs1799913 42 0.096 0.017 41 0.334 0.342
TPH1 rs684302 42 0.232 0.017 41 0.171 0.397
DDC rs9942686 21 0.723 0.018 23 1.000 0.189
MAOB (men) rs6651806 24 0.021 32 0.328
DDC rs17133853 11 1.000 0.033 9 0.569 0.436
DBH rs1611115 21 1.000 0.035 14 1.000 0.791
DBH rs3025388 18 0.445 0.047 18 0.517 0.064
TPH1 rs12292915 44 0.161 0.047 43 0.052 0.066
TPH1 rs211105 31 0.785 0.049 25 0.449 0.033
Minor allele frequencies (MAF), p-values of testing for Hardy–Weinberg equilibrium (HWE) and p-values (P) from multiple linear regressions of single nucleotide
polymorphisms (SNPs) nominally associated with 3-methoxy-4-hydroxyphenylglycol (MHPG) concentrations in the cerebrospinal fluid of psychotic patients and
the corresponding association statistics among healthy controls. MAOA and MAOB are located on chromosome X and the analyses were therefore conducted
separately for men and women.
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pendent variables, i.e. the SNPs, are not expected to be
associated with the presence or absence of antipsychotic
treatment. Thus, the use of antipsychotics should not
confound our analyses, even in the case of MHPG.
Discussion
In the present study, polymorphisms in genes coding for
enzymes of importance for the catecholamine and sero-
tonin metabolism were analyzed. There was an excess of
nominally significant associations (42 observed versus 20
expected) among patients with psychotic disorder.
The Hardy-Weinberg principle is used in association
studies to detect genotyping errors, inbreeding and popula-
tion stratification [31]. Deviation from the Hardy-Weinberg
proportions in psychotic individuals can provide evidence
for association between SNPs and psychosis [31]. In the
present study four SNPs showed departure from HWE
(p < 0.05) in psychotic patients, i.e. DDC rs4947510, DDC
rs921451, TPH2 rs1352250 and COMT rs165774. Depar-
ture from HWE in controls can indicate genotyping errors,
inbreeding or population stratification [31]. Lack of HWE
may also result as an effect of multiple testing. In the
present study, two SNPs showed departure from HWE(p < 0.05) in healthy controls, i.e. TPH1 rs7122118 and
TPH1 rs4537731. The results regarding these SNPs should
be interpreted with caution.
TPH1 and TPH2
TPH1 gene variations have been associated with schizophre-
nia in several studies including meta-analyses (www.szgene.
org). In the present study, one TPH1 SNP, i.e. rs1799913,
was nominally associated with 5-HIAA concentrations.
Rs1799913 has been associated with schizophrenia in sin-
gle studies including a meta-analysis (www.szgene.org).
We could therefore hypothesize that the previously
reported association between TPH1 rs1799913 and
schizophrenia may be mediated by serotonergic mecha-
nisms and altered serotonin turnover rate in CNS.
One and seven TPH1 SNPs were associated with HVA
and MHPG concentrations, respectively. Four of the
polymorphisms associated with MHPG concentrations,
including rs1799913, have previously been reported to
be associated with schizophrenia (www.szgene.org).
One TPH2 SNP has been associated with the severity of
positive psychotic symptoms in patients with schizophrenia
[32]. In the present study TPH2 rs1872824 was found to
be associated with CSF HVA, whereas no association was
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concentrations.
TH
TH gene variants have been associated with schizophrenia
in 6 out of 19 studies. However, in a meta-analysis no
association could be confirmed (www.szgene.org). More-
over,TH gene variation has been reported to be associated
with CSF HVA and MHPG concentrations in healthy
controls [33].
In the present study three TH SNPs, i.e. rs10770141,
rs10840491 and rs10840489, were associated with HVA
concentrations in patients with psychosis. Rs1077014, lo-
cated upstream of TH in the proximal promoter, affects
the transcriptional activity of the promoter and the cat-
echolamine secretion in humans [34]. Rs1077014 may be
associated with persistence, a typical personality trait in
chronic fatigue syndrome patients [35] as well as with the
personality trait of novelty seeking in healthy men [36].
To our knowledge rs10840491 and rs10840489 have not
been ascribed any functionality or association with schizo-
phrenia or other mental disorders.
DDC
No studies have shown significant associations between
DDC SNPs and schizophrenia (www.szgene.org), whereas
an association between DDC genotypes and age at disease
onset has been found in men with schizophrenia [37].
Moreover, DDC deficiency has been reported to result in
decreased HVA and 5-HIAA concentrations in CSF [38,39].
In the present study six, four and five DDC SNPs, all in-
tronic, were nominally associated with CSF HVA, 5-HIAA
and MHPG concentrations, respectively. Rs6592961 has
been reported to be significantly associated with autism
[40]. In the present study, this SNP was nominally associ-
ated with MHPG concentrations in psychotic patients.
DBH
In the present study, two DBH SNPs, i.e. rs1611118
and rs6271 and three DBH SNPs, i.e. rs6271, rs1611115,
and rs3025388 were found to be nominally associated
with 5-HIAA and MHPG concentrations, respectively, in
psychotic patients. Rs1611115, located upstream of DBH,
accounts for 31% to 52% of the variance of plasma DBH
activity in different human populations [41], whereas
rs6271, a nonsynonymous SNP located in exon 11,
independently accounts for additional variance [42].
DBH SNPs have been associated with schizophrenia in
2/17 studies conducted (www.szgene.org). Rs1611115 has
been significantly associated with attention-deficit hyper-
activity disorder in children [43], as well as with impulsive-
ness and aggressive hostility in adults [44]. Moreover, this
SNP has been found to be associated with alcohol depen-
dence in women [45]. Rs6271 was nominally associatedwith schizophrenia in both case–control and family based
analyses in a north Indian schizophrenia cohort [46] and
significantly associated with bipolar disorder in a Turkish
population [47]. Rs1611118 and rs3025388 are intronic
and to our knowledge, have not been ascribed any func-
tionality or association with mental disorders.
COMT
COMT is a candidate gene for schizophrenia with many
studies, including meta-analyses, reporting association be-
tween gene polymorphisms and the disorder (www.szgene.
org). COMT gene variations have not shown associations
with monoamine metabolite concentrations in healthy con-
trols or in a mixed group of psychiatric patients [48,49]. In
the present study, the intronic COMT rs165774 was nom-
inally associated with HVA concentrations. Rs165774
showed departure from Hardy-Weinberg equilibrium in
psychotic patients but not in healthy controls. Rs165774
has been reported to be significantly associated with schizo-
phrenia [50] and alcohol dependence [51].
MAOA and MAOB
A minority of studies searching for association between
MAOA or MAOB gene variation and schizophrenia re-
ported a relationship (2/29 and 3/15, respectively) (www.
szgene.org). MAOA polymorphisms have been associated
with CSF HVA concentrations in patients with atypical
depression [52], alcohol dependence and controls [53,54]
as well as in a mixed group of psychiatric patients [49].
MAOA polymorphisms have also been associated with 5-
HIAA in healthy men [55] and women [54].
In the present study, threeMAOA SNPs were associated
with 5-HIAA concentrations in psychotic men (Table 2),
whereas three MAOB SNPs were associated with MHPG
concentrations in psychotic men (Table 3) and twoMAOB
SNPs were associated with 5-HIAA concentrations in
psychotic women (Table 2).
The associations between MAOB rs5905512 and MAOB
rs1799836 and MHPG concentrations displayed the lowest
p-values in the present study.MAOB rs5905512 was associ-
ated with MHPG concentrations in psychotic men (uncor-
rected p = 0.0004), which is statistically significant taking
into account only the candidate SNPs tested. No associ-
ation was found between rs5905512 and psychotic women,
healthy men or healthy women. To our knowledge, two
studies have searched for association between this SNP and
schizophrenia (www.szgene.org) and our results are in ac-
cordance with one of these two studies [56], reporting sig-
nificant association between rs5905512 and schizophrenia
only in men, whereas the other study did not find any asso-
ciations in either gender [57]. Moreover, rs5905512, located
in intron 1, is a perfect proxy of a haplotype spanning from
intron 1 to intron 3 and being subject to recent selection,
in agreement with the ancestral susceptibility hypothesis of
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with MHPG concentrations in men with psychosis
(uncorrected p = 0.001) in the present study. Rs1799836 is
located in intron 13 and is associated with altered enzyme
activity in vitro and in vivo [58,59]. Rs1799836 has been
associated with schizophrenia in women [60]. The third
MAOB SNP that was found to be associated with MHPG
concentrations in psychotic men, i.e. rs6651806, has previ-
ously been reported to be associated with negative emo-
tionality in healthy individuals [61]. To our knowledge, no
functionality or association with mental disorders has
been ascribed to the other MAOA (rs5906957, rs4301558,
rs3027396) and MAOB (rs2311013, rs1181252) variants
showing nominal association with monoamine metabo-
lites in the present study.
Limitations
The present study has certain limitations. The relatively
small number of participants, both patients and controls,
in association with the large number of tests conducted,
results in a limited power to detect possible associations
between SNPs and CSF monoamine metabolite concen-
trations after correction for multiple testing. Moreover,
the non-inclusion of tobacco use as a covariate may
influence the results, especially with regard to HVA
concentrations [62]. Finally, the associations found in the
present study need replications in independent studies.
Conclusions
In psychotic patients, we found nominal associations
between SNPs in genes encoding enzymes implicated in
the monoamine pathways and the CNS monoamine
turnover rates, as reflected by the CSF concentrations of
HVA, 5-HIAA and MHPG. There were 42 nominal asso-
ciations, which exceed the expected number (20) of
nominal associations given the total number of tests
performed. Forty-one out of these 42 suggestive associa-
tions were restricted to patients with psychosis and were
absent in healthy controls. Some of the associated SNPs
have been reported to be associated with schizophrenia.
Moreover, one candidate MAOB SNP, previously
reported to be associated with schizophrenia in men,
was found to be significantly associated with MHPG
concentrations in men with psychotic disorder, perfor-
ming a correction for multiple testing for the number of
candidate SNPs selected. Taken together, the present
study supports the notion that altered monoamine turn-
over rates reflect intermediate steps in the associations
between gene variations and psychosis.
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